New study tracks Brigatinib's Real-World impact on chinese lung cancer patients
NCT ID NCT05721950
First seen Feb 28, 2026 · Last updated May 13, 2026 · Updated 13 times
Summary
This study looks at how long Chinese patients with a specific type of advanced lung cancer (ALK-positive NSCLC) stay on the drug brigatinib when it's their first treatment. Researchers will also track how well the drug controls the cancer over time. The study does not give any new treatment—it simply observes patients who are already taking brigatinib as part of their normal care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Oncology, Shanghai pulmonary hospital
Shanghai, Shanghai Municipality, 200433, China
Conditions
Explore the condition pages connected to this study.